Vanda Pharmaceuticals (VNDA) EBIAT (2016 - 2025)
Vanda Pharmaceuticals (VNDA) has disclosed EBIAT for 16 consecutive years, with -$141.2 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 2774.33% to -$141.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$220.5 million through Dec 2025, down 1066.53% year-over-year, with the annual reading at -$220.5 million for FY2025, 1066.53% down from the prior year.
- EBIAT hit -$141.2 million in Q4 2025 for Vanda Pharmaceuticals, down from -$22.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $9.7 million in Q2 2021 to a low of -$141.2 million in Q4 2025.
- Historically, EBIAT has averaged -$9.9 million across 5 years, with a median of -$1.1 million in 2023.
- Biggest five-year swings in EBIAT: soared 1679.84% in 2021 and later crashed 3986.13% in 2024.
- Year by year, EBIAT stood at $7.1 million in 2021, then decreased by 3.07% to $6.9 million in 2022, then crashed by 134.98% to -$2.4 million in 2023, then plummeted by 104.67% to -$4.9 million in 2024, then tumbled by 2774.33% to -$141.2 million in 2025.
- Business Quant data shows EBIAT for VNDA at -$141.2 million in Q4 2025, -$22.6 million in Q3 2025, and -$27.2 million in Q2 2025.